Phenotype of mesenchymal stem cells from patients with myelodyplastic syndrome maybe partly modulated by decitabine

Mesenchymal stem cells (MSCs) derived from myelodysplastic syndromes (MDSs) have been demonstrated to accelerate the progression of MDS. However, whether the phenotype of MSCs derived from MDS (MDS-MSCs) may be reversed and serve as a potential target for the treatment of MDS remains unclear. The pr...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncol Lett
Huvudupphovsmän: Pang, Yanbin, Geng, Suxia, Zhang, Hongyang, Lai, Peilong, Liao, Pengjun, Zeng, Lingji, Lu, Zesheng, Weng, Jianyu, Du, Xin
Materialtyp: Artigo
Språk:Inglês
Publicerad: D.A. Spandidos 2019
Ämnen:
Articles
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6781515/
https://ncbi.nlm.nih.gov/pubmed/31611955
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2019.10788
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk